Your browser doesn't support javascript.
loading
[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté]. / Prévalence et prise en charge de la douleur chez les patients présentant un cancer métastatique en Franche-Comté.
Dénommé, Fanny; Kroemer, Marie; Montcuquet, Philippe; Nallet, Gilles; Thiery-Vuillemin, Antoine; Bazan, Fernando; Mouillet, Guillaume; Villanueva, Cristian; Demarchi, Martin; Stein, Ulrich; Almotlak, Hamadi; Chaigneau, Loïc; Curtit, Elsa; Meneveau, Nathalie; Maurina, Tristan; Dobi, Erion; Hon, Thierry Nguyen Tan; Cals, Laurent; Mansi, Laura; Verlut, Clotilde; Pana-Katatali, Héloïse; Caubet, Mathieu; Paillard, Marie-Justine; Limat, Samuel; Pivot, Xavier; Nerich, Virginie.
Afiliação
  • Dénommé F; CHRU de Besançon, pôle pharmacie, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Kroemer M; CHRU de Besançon, pôle pharmacie, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France.
  • Montcuquet P; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Nallet G; Oncolie, réseau de cancérologie de Franche-Comté, pôle cancérologie, 2, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Thiery-Vuillemin A; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Bazan F; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Mouillet G; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Villanueva C; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Demarchi M; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Stein U; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Almotlak H; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Chaigneau L; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Curtit E; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Meneveau N; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Maurina T; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Dobi E; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Hon TN; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Cals L; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Mansi L; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Verlut C; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Pana-Katatali H; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Caubet M; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Paillard MJ; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Limat S; CHRU de Besançon, pôle pharmacie, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France.
  • Pivot X; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France; CHRU de Besançon, service d'oncologie médicale, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France.
  • Nerich V; CHRU de Besançon, pôle pharmacie, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France. Electronic address: v1nerich@chu-besancon.fr.
Bull Cancer ; 103(10): 849-860, 2016 Oct.
Article em Fr | MEDLINE | ID: mdl-27692731
ABSTRACT

INTRODUCTION:

Pain management is a major public health problem, especially in oncology. In order to assess professional practice, the IRFC-FC conducted a survey amongst patients with metastatic osteophilic solid tumor in Franche-Comté. The aims were to assess the pain prevalence, and its characteristics, its management and its impact on patients' quality of life in patients in pain.

METHODS:

An observational, prospective and multicenter survey was conducted using a self-report questionnaire. Patients with metastatic breast or prostate cancer managed in 5 day-hospitals of the IRFC-FC over a period of three months were included.

RESULTS:

Two hundred thirty-three questionnaires were analyzed. Pain prevalence rate was 48.5%. Three quarters of patients in pain had chronic background pain, moderate to severe, with or without breakthrough pain. Considering their pain intensity and their analgesic therapy, 42.0% of patients seem to have an inadequate treatment. Eighty-five percent of treated patients reported to be compliant and felt that their pain was well managed despite a strong impact on their quality of life.

CONCLUSION:

The setting of a specific clinical pathway is essential to secure the standardized, optimal and efficient management of patients in pain. The assessment of patient satisfaction and quality of life must be integrated in clinical practice to identify patients in pain for which the treatment is inappropriate.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias da Mama / Dor Crônica / Manejo da Dor / Analgésicos Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: Fr Revista: Bull Cancer Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias da Mama / Dor Crônica / Manejo da Dor / Analgésicos Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: Fr Revista: Bull Cancer Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França